ClinicalTrialsFinder
RecruitingPhase 1NCT06639503

Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau

Genicular Nerve Block for Analgesia After Open Reduction Internal Fixation of Tibial Plateau Fractures: A Prospective, Randomized Controlled Trial

Sponsor

University of Chicago

Enrollment

38 participants

Start Date

Nov 1, 2024

Study Type

INTERVENTIONAL

Conditions

Tibial Plateau Fractures

Summary

The investigators are conducting this research study to find better ways of treating pain following knee surgery. There is a standard (accepted) approach, which involves injection of numbing medication into the area around the participant surgical incision. The investigators hope to discover if providing numbing medication to a nerve that controls pain in a larger area of the knee (a nerve block), might be better at post-operative pain control.

Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Any adult patient (ages 18 and over) undergoing open reduction internal fixation of an acute isolated tibial plateau fracture

Exclusion Criteria18

  • Subjects younger than 18
  • Polytraumatized Subjects
  • Subjects with pathologic fractures
  • Subjects with tibial plateau fractures treated nonoperatively
  • Subjects with tibial plateau fractures treated operatively but with re-operations at the same site
  • Subjects with open fractures
  • Subjects with fracture-dislocations
  • Subjects with active or history of anxiety
  • Subjects with visual analog scale anxiety score ≥ 7 measured preoperatively
  • Subjects with chronic pain syndromes
  • Subjects with chronic opioid use
  • Subjects with illicit drug use disorder
  • Subjects with alcohol abuse disorder
  • Subjects with kidney disease precluding use of ketorolac
  • Subjects with liver disease precluding the use of acetaminophen
  • Subjects with allergy to acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), opiates or local anesthesia
  • Subjects with inability to provide a visual analog scale score postoperatively
  • Subjects with contraindications to receiving peripheral nerve blocks, including relevant neurologic deficits, active infection at sites of injections - re-operation at the same site

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBupivacain

5mL 0.25% bupivacain

Locations(1)

University of Chicago

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06639503